Cancer Prevention and Control

癌症预防和控制项目概要 癌症预防和控制（CPC）计划致力于定义，评估和实施 新的干预措施，以降低癌症发病率，最大限度地减少疾病和治疗相关的症状， 提高整体生存率。CPC研究人员采用最先进的药物、检测和研究设计 在2个优先领域推进该领域：1）减少癌症风险，包括化学预防，烟草 控制，癌症早期发现研究; 2）症状控制和生存，整合基础， 临床和社区研究，以改善癌症护理。这一重点框架提供了 一个有效的结构，在癌症预防和癌症控制方面进行创新和合作研究 设置. CPC风险降低研究活动集中在抑制浸润前肿瘤， 排除（或降低）烟草暴露，并在尽可能早的阶段识别无症状的肿瘤。 对于症状控制和生存，研究活动旨在消除或控制不良反应， 与疾病进展或治疗相关的症状，以及优化治疗后的生活质量和数量。 癌症诊断为了实现其预期目标，CPC计划组建了一个跨学科的团队， 来自所有3个马约诊所校区的20个部门的50名成员。直接同行评审资金总额为 410万美元（54%来自NCI），直接资助总额为520万美元。自2013年以来，该计划已产生661 出版物，26%反映方案内合作，33%反映方案间合作 合作。在每个方案目标方面都作出了显著贡献， 将研究结果纳入化学预防剂开发计划，临床实践标准， 和公共卫生政策。Loprinzi博士与林布尔格博士一起沿着领导CPC项目，林布尔格博士加入了 2017年6月的领导二人组。在这种领导配对下，该计划重新组织了其研究 活动，为加速有影响力的研究提供坚实的基础，并推出了几个新的 增加CPC计划与其他主要内部和外部组织之间合作机会的举措 外部利益相关者团体。预计未来5年的主要CPC计划活动包括： 进行尖端的，以团队为基础的研究，涉及发现，翻译和应用 有前途的化学预防剂，癌症疫苗，戒烟和尼古丁避免策略， 早期检测生物标志物，多器官筛查方法（如“液体活检”），成像技术， 症状管理和生存护理。该计划广泛利用共享资源， 特别是：生物标本的收集和处理（BAP），生物统计学（BSR），基因组分析 (GEN)、药学部（PHM）和MCCC临床研究办公室（CRO）。

CANCER PREVENTION AND CONTROL PROGRAM PROJECT SUMMARY The Cancer Prevention and Control (CPC) Program is engaged in defining, evaluating, and implementing novel interventions to reduce cancer incidence, minimize disease- and treatment-related symptoms, and enhance overall survivorship. CPC investigators apply state-of-the-science agents, assays, and study designs to advance the field in 2 prioritized areas: 1) Cancer Risk Reduction, including chemoprevention, tobacco control, and cancer early detection research; and 2) Symptom Control & Survivorship, integrating basic, clinical, and community-based studies to improve cancer care. This intentionally focused framework provides an efficient structure for innovative, collaborative investigation in both the cancer prevention and cancer control settings. CPC Risk Reduction research activities are concentrated on inhibiting preinvasive neoplasia, precluding (or lowering) tobacco exposure, and identifying asymptomatic tumors at the earliest possible stage. For Symptom Control and Survivorship, research activities are directed at eliminating or controlling untoward symptoms related to disease progression or treatment, and optimizing quality and quantity of life following a cancer diagnosis. To achieve its intended goals, the CPC Program has assembled an interdisciplinary team of 50 members from 20 departments across all 3 Mayo Clinic campuses. Total direct peer-reviewed funding is $4.1M (54% from the NCI), and total direct funding is $5.2M. Since 2013, the Program has generated 661 publications, 26% reflecting intraprogrammatic collaborations and 33% reflecting interprogrammatic collaborations. Notable contributions have been made with respect to each Program aim, as evidenced by the incorporation of study results into chemoprevention agent development planning, clinical practice standards, and public health policies. Dr. Loprinzi co-leads the CPC Program along with Dr. Limburg, who joined the leadership dyad in June 2017. Under this leadership pairing, the Program has reorganized its research activities to provide a strong foundation for accelerating impactful research and has also launched several new initiatives to increase opportunities for collaboration between the CPC Program and other key internal and external stakeholder groups. Major CPC Program activities anticipated for the next 5 years include further conduct of cutting-edge, team-based research related to the discovery, translation, and application of promising chemoprevention agents, cancer vaccines, tobacco cessation and nicotine avoidance strategies, early-detection biomarkers, multi-organ screening approaches (such as “liquid biopsy”), imaging technologies, symptom management, and survivorship care. The Program makes extensive use of Shared Resources, in particular: Biospecimens Accessioning and Processing (BAP), Biostatistics (BSR), Genome Analysis (GEN), Pharmacy (PHM) and the MCCC Clinical Research Office (CRO).